A craniopharyngioma is a rare, slow-growing brain tumor that develops near the pituitary gland at the base of the skull. It is classified as a grade I tumor by the World Health Organization, meaning it is not cancerous, but its location next to critical brain structures makes it capable of causing serious hormonal, visual, and neurological problems. These tumors account for 5 to 11 percent of brain tumors in children and also occur in adults, with a second peak between ages 50 and 74.
Where Craniopharyngiomas Come From
Craniopharyngiomas grow from leftover cells of Rathke’s pouch, a small pocket of tissue that forms the front part of the pituitary gland during fetal development. Normally, these remnant cells are harmless and inactive. In rare cases, they begin to grow abnormally and form a tumor in the sellar region, the bony pocket at the base of the brain that houses the pituitary gland. Because of this origin, the tumor sits in close contact with the pituitary gland, the optic nerves, and the hypothalamus, a part of the brain that controls hunger, body temperature, sleep, and hormone signaling.
Two Distinct Subtypes
There are two types of craniopharyngioma, and they differ in who they affect and how they behave at the cellular level.
The adamantinomatous type is the most common form in children. Under a microscope, it shows characteristic patterns of layered tissue, calcium deposits, inflammation, and clusters of “ghost cells,” which are pale, empty-looking cells. These tumors frequently contain fluid-filled cysts and areas of hardened calcium that show up clearly on imaging. They arise from embryonic remnant cells.
The papillary type is seen almost exclusively in adults, with an average age at diagnosis around 46. It tends to be more solid and less calcified. Over 90% of papillary craniopharyngiomas carry a specific genetic mutation called BRAF V600E, which has become an important treatment target.
Common Symptoms
Because craniopharyngiomas sit at a hormonal and neurological crossroads, they produce a wide range of symptoms depending on which nearby structures they press on.
Hormonal Disruption
The tumor’s proximity to the pituitary gland means hormone deficiencies are often the earliest and most common problem. In children, the most frequently affected hormones are growth hormone (62% of cases) and thyroid hormone (60%), followed by the stress hormone cortisol (54%), the hormone that controls water balance (42%), and sex hormones (41%). Adults show a somewhat different pattern: thyroid hormone is most commonly affected (56%), followed by sex hormones (48%) and growth hormone (38%). Up to 80% of adults with craniopharyngioma develop complete pituitary failure, requiring lifelong hormone replacement.
Vision Problems
The tumor often grows upward and presses on the optic nerves or the point where they cross. This typically causes a loss of peripheral vision on both sides, though the specific pattern depends on the tumor’s size and exact position.
Increased Pressure in the Skull
Larger tumors can block the normal flow of cerebrospinal fluid, causing headaches, nausea, and vomiting from rising pressure inside the skull. In children, this is sometimes the symptom that first brings the tumor to attention.
How It Is Diagnosed
Craniopharyngiomas have a distinctive appearance on brain imaging. CT scans are particularly good at revealing calcification, which is present in most adamantinomatous tumors and shows up as bright white spots. MRI is better at revealing the full extent of the tumor, including cystic (fluid-filled) and solid components, and how the tumor relates to surrounding brain structures. In studies comparing the two, CT detected calcification in 7 out of 9 tumors while MRI identified cystic components that CT missed. Most patients get both types of imaging. Blood tests measuring pituitary hormone levels round out the diagnostic picture.
Surgical Treatment Options
Surgery is the primary treatment for craniopharyngioma. There are two main approaches, and the choice depends on the tumor’s size, location, and relationship to surrounding structures.
The endoscopic endonasal approach reaches the tumor through the nose and sinuses, avoiding the need to open the skull. A large meta-analysis found this approach is significantly more effective at achieving complete tumor removal compared to the traditional route. It also produces better visual outcomes, with patients roughly twice as likely to see improvement in their vision afterward. Recurrence rates are lower as well.
The transcranial approach involves opening the skull to access the tumor from above. While it was associated with fewer immediate neurological complications in the same analysis, it had higher tumor recurrence rates and was less likely to achieve complete removal. Mortality rates were similar for both approaches.
Because complete removal carries a risk of damaging the hypothalamus, many surgeons now favor a strategy of removing as much tumor as safely possible while preserving hypothalamic function, then using radiation to control any remaining tumor.
Radiation After Surgery
Radiation therapy is highly effective at preventing regrowth after partial tumor removal. Two forms are commonly used: traditional photon-based radiation and proton beam therapy. Proton therapy deposits less stray radiation to surrounding healthy tissue, which in theory should reduce long-term side effects.
A study from the KRANIOPHARYNGEOM 2007 trial compared the two in children and found nearly identical five-year disease control rates: 92% for proton therapy versus 91% for photon radiation. Radiation doses reaching the hypothalamus and pituitary were also similar between the two methods. Over five years of follow-up, there were no meaningful differences in functional capacity, body weight, or quality of life between children who received either type of radiation. Potential advantages of proton therapy in reducing vascular problems or secondary cancers may take longer to appear.
Hypothalamic Obesity
One of the most challenging complications after craniopharyngioma treatment is severe weight gain caused by hypothalamic damage, occurring in up to 75% of survivors. This is not ordinary weight gain. It happens even when calorie intake is restricted, and standard diet and exercise approaches are essentially ineffective against it.
The underlying problem is that the damaged hypothalamus can no longer read the body’s fullness signals, particularly leptin, the hormone fat cells release to signal that energy stores are adequate. The brain effectively behaves as if the body is starving: it slows metabolism, reduces energy expenditure, and ramps up insulin production, which drives fat storage. This creates a cycle of weight gain that resists conventional treatment.
Managing this condition is difficult. Medications that boost the body’s “burn” signals or suppress excess insulin production have been tried with mixed results. Bariatric surgery, including gastric bypass and gastric banding, has also been attempted, but outcomes vary. Early and aggressive intervention gives the best chance of limiting weight gain.
Targeted Drug Therapy for Papillary Tumors
A significant development has emerged for papillary craniopharyngiomas. Because over 90% carry the BRAF V600E mutation, researchers tested a combination of two drugs that block this mutation’s effects. In a phase 2 trial published in the New England Journal of Medicine, 15 of 16 patients (94%) with newly diagnosed papillary craniopharyngiomas had meaningful tumor shrinkage with this drug combination. These results were striking enough that the study authors suggested doctors could consider doing only a biopsy to confirm the mutation, then treating with medication rather than attempting aggressive surgery upfront.
Long-Term Outlook
Craniopharyngiomas have high survival rates. The 10-year overall survival across large studies is 80 to 93%. One pediatric study found 5-year survival of 100% and 15-year survival of nearly 95%. The main long-term challenge is not survival but quality of life: managing hormone deficiencies, monitoring for tumor recurrence, and coping with complications like hypothalamic obesity and vision changes.
Tumor recurrence is common, with progression-free survival dropping from about 85% at five years to around 70% at ten and fifteen years. This means regular follow-up imaging and hormone monitoring are a permanent part of life after treatment. Most patients require lifelong replacement of multiple pituitary hormones, including thyroid hormone, cortisol, sex hormones, growth hormone, and sometimes the hormone that prevents excessive urination. The frequency and complexity of this ongoing care make long-term management by a specialized endocrine team essential.